Catalyst
Slingshot members are tracking this event:
Crinetics Pharma's (CRNX) Phase 1 of CRN04777 to reduce stimulated insulin secretion for treatment of children with Congenital isolated hyperinsulinism - Results expected mid 2021
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CRNX | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 15, 2021
Occurred Source:
https://crinetics.com/crn04777-demonstrates-dose-dependent-supression-of-insulin-secretion-phase1-sad-study/
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Congenital Isolated Hyperinsulinism, Crn04777
